Spondyloarthritis (Psoriatic Arthritis and Axial Spondyloarthritis) Patient-Centered Experience Initiating Bimekizumab in Routine Clinical Practice: A Multi-Country, Prospective, Observational Study (SPEAK)

Research summary

The overall aim of this observational study is to evaluate Patient Reported Outcomes (PROs), including Health-related Quality of Life (HRQoL), and to describe characteristics of psoriatic arthritis (PsA) and axial spondylitis (axSpA) (nonradiographic [nr]-axSpA and radiographic [r]-axSpA) patients following bimekizumab treatment initiation over time in routine clinical practice. To improve medical care continuously, it is thus very important to collect further data on the use of a drug outside of regulated clinical trials. The purpose of this study is • to observe how Bimekizumab is used in routine clinical practice • to learn what the experiences of patient are with Bimekizumab in terms of their health-related quality of life • to evaluate whether there are any changes in the level of disease activity • to characterize patients with PsA and r-/nr-axSpA in greater detail. There will be no study-specific assessments or clinical appointments, and patients will be treated in the usual way. Patients will be asked to electronically complete some questionnaires regarding the severity of their disease and how the symptoms might affect their life (health-related quality of life). The trial is a multi-centre taking place in 10 sites in the UK with the aim to recruit 100 patients. The trial will take place over a period of 2.5 years.

Principal Investigator

Prof Laura Coates

Contact us

Email: gail.lang@ndorms.ox.ac.uk

IRAS number

333184